Nautilus Biotechnolgy, Inc. - Current Ratio

The Current Ratio as of August 2026 (TTM) for Nautilus Biotechnolgy, Inc. (NAUT) is 10.14

According to Nautilus Biotechnolgy, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.14. This represents a change of -19.29% compared to the average of 12.57 of the last 4 quarters.

Nautilus Biotechnolgy, Inc. (NAUT) Historical Current Ratio (quarterly & annually)

How has NAUT Current Ratio performed in the past?

The mean historical Current Ratio of Nautilus Biotechnolgy, Inc. over the last ten years is 58.07. The current 10.14 Current Ratio has changed 1.65% with respect to the historical average. Over the past ten years (40 quarters), NAUT's Current Ratio was at its highest in in the December 2018 quarter at 266.45. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Nautilus Biotechnolgy, Inc. (NAUT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Nautilus Biotechnolgy, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nautilus Biotechnolgy, Inc. (NAUT) Average Current Ratio

How has NAUT Current Ratio performed in the past?

The current Current Ratio of Nautilus Biotechnolgy, Inc. (NAUT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Nautilus Biotechnolgy, Inc. (NAUT) Current Ratio vs. Peers

How is NAUT’s Current Ratio compared to its peers?

Nautilus Biotechnolgy, Inc.’s Current Ratio is greater than Foghorn Therapeutics Inc. (2.92), less than Immuneering Corporation (19.47), greater than Enanta Pharmaceuticals, Inc. (3.84), greater than Pyxis Oncology, Inc. (2.76), greater than Tenaya Therapeutics, Inc. (5.75), less than Zura Bio Limited (19.33), greater than Assembly Biosciences, Inc. (6.65), greater than Humacyte, Inc. (3.93), less than Sagimet Biosciences Inc. (20.34), greater than Arcturus Therapeutics Holdings Inc. (6.31),

Build a custom stock screener for Nautilus Biotechnolgy, Inc. (NAUT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nautilus Biotechnolgy, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nautilus Biotechnolgy, Inc. (NAUT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nautilus Biotechnolgy, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.